Abstract: The monoclonal antibody of programmed cell death protein 1 (PD-1) can block the interaction between PD-1 and its ligand, meanwhile also restore the anti-tumor immunity of T cells. PD-1 inhibitors are approved widely for the treatment of various types of malignancies. A large number of literatures have explained the excellent anti-tumor effects of Sindilizumab as well as some side effects. But it is very rare to see acute autoimmune insulin-dependent diabetes mellitus caused by PD-1 inhibitors in children. We now report one child with hyperglycemia after using PD-1 inhibitors in The First Affiliated Hospital of Guangdong Pharmaceutical University in November 2021.

Key words: Programmed cell death protein 1, Diabetes mellitus, Children

摘要： 程序性细胞死亡蛋白1（PD-1）的单克隆抗体可以阻断PD-1与其配体之间的相互作用，恢复T细胞的抗肿瘤作用。PD-1抑制剂已被广泛批准用于治疗各种恶性肿瘤。有大量文献报道了信迪利单抗有令人满意的抗肿瘤作用，同时也报道出一些相关不良反应。由PD-1抑制剂引起的急性自身免疫性胰岛素依赖型糖尿病在儿童中非常罕见。现报道广东药科大学附属第一医院2021年11月收治的1例应用PD-1抗体后出现高血糖症儿童。

关键词: 程序性细胞死亡蛋白1, 糖尿病, 儿童